EUCTR2009-009256-20-IE进行中（未招募）不适用
Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBC
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 380 人开始时间: 2009年9月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 380
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •1. CD20 positive DLBCL. Biopsies performed after termination of first-line treatment must confirm CD20 positive DLBCL.
- •2. Refractory to, or relapsed following, first-line treatment with rituximab combined with anthracycline-based chemotherapy. Relapse is defined as biopsy confirmed CD20 positive DLBCL after a complete response.
- •Refractory disease must fulfill one of the following:
- •partial response (PR) after termination of first-line treatment. Subjects must have received at least 6 cycles of rituximab combined with anthracycline-based chemotherapy. Subjects with stage I/II disease will also be eligible if treated with at least 3 cycles of rituximab combined with anthracycline-based chemotherapy and definitive involved-field radiation therapy. Biopsy confirmation of CD20 positive DLBCL is required.
- •stable disease (SD) after termination of first-line treatment. Subjects must have received at least 3 cycles of rituximab combined with anthracycline-based chemotherapy. Biopsy confirmation of CD20 positive DLBCL is preferred but not required.
- •progressive disease (PD). Biopsy confirmation of CD20 positive DLBCL is preferred but not required.
- •Disease response to first-line treatment should be determined according to Revised Response Criteria for Malignant Lymphoma [Cheson, 2007], or if PET scanning was not used, International Workshop Response criteria for NHL [Cheson, 1999].
- •3. Baseline FDG-PET scans must demonstrate positive lesions compatible with CT defined anatomical tumor
- •4. CT scan showing at least:
- •2 or more clearly demarcated lesions/nodes with a largest diameter =1.5 cm and not previously irradiated
- •1 clearly demarcated lesion/node with a largest diameter =2.0 cm and not previously irradiated.
- •5. Age =18
- •6. ECOG performance status 0, 1, or 2.
- •7. Eligible for high dose chemotherapy and ASCT.
- •8. Resolution of toxicities from first-line therapy to grade=1.
- •9. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •1. Any previous cancer therapy for DLBCL, with the exception of:
- •First-line treatment with rituximab in combination with an anthracycline-based chemotherapy.
- •Radiotherapy as part of the first-line treatment plan or to a limited field at a maximum dose of =10Gy to control
- •life-threatening symptoms.
- •2. Received any of the following treatments within 4 weeks prior to start of study therapy (unless otherwise
- •Anti-cancer therapy (e.g. alkylating agents, anti-metabolites, purine analogues)
- •Radiotherapy unless it is to a limited field at a maximum dose of =10Gy to control life-threatening symptoms.
- •3. Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study
- •4. Glucocorticoid use, unless given in doses =100mg/day hydrocortisone (or equivalent dose of other glucocorticoid-refer to the SPM for glucocorticoid equivalent doses) for <7 days for exacerbations other than lymphoma (e.g. asthma)
- •5. History of significant cerebrovascular disease or event with significant symptoms or sequelae.
- •6. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomisation, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
- •7. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease.
- •8. Known DLBCL involvement of the CNS.
- •9. Known or suspected hypersensitivity to study treatments that, in the opinion of the investigator or GSKmedical Monitor, contraindicates their participation
- •10. Known HIV positivity.
- •11. Positive serology for hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive and HBsAb negative, a HB DNA test will be performed and if positive the subject will be excluded. Note: If HBcAb positive and HBsAb positive, which is indicative of a past infection, the
- •subject can be included.
- •12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result.
- •13. Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis and tuberculosis.
- •14. Other past or current malignancy. However, subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
- •15. Prior treatment with anti-CD20 monoclonal antibodies with the exception of rituximab or treated with other monoclonal antibodies within 3 months prior to start of study therapy.
- •16. Screening laboratory values:
- •platelets <50 x 10^9/L (unless due to DLBCL involvement of the bone marrow)
- •neutrophils <1.0 x 10^9/L (unless due to DLBCL involvement of the bone marrow)
- •creatinine >2.0 times upper normal limit (unless normal creatinine clearance)
- •total bilirubin >1.5 times upper normal limit (unless due to DLBC
研究者
相似试验
进行中（未招募）
不适用
Ofatumumab for the treatment of lymphomaDiffuse Large B-Cell Lymphoma (DLBCL) and grade 3b follicularlymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009256-20-PLGlaxoSmithKline Research and Development Limited380
进行中（未招募）
不适用
Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCEUCTR2009-009256-20-ESGlaxoSmithKline S.A.380
进行中（未招募）
不适用
Ofatumumab for the treatment of lymphomaDiffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 14.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-009256-20-GRGlaxoSmithKline Research and Development Limited380
进行中（未招募）
1 期
Ofatumumab for the treatment of lymphomaleaseEUCTR2009-009256-20-GBGlaxoSmithKline Research and Development Limited447
进行中（未招募）
不适用
Ofatumumab for the treatment of lymphomaDiffuse Large B-Cell Lymphoma (DLBCL) and grade 3b follicular lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2009-009256-20-DEGlaxoSmithKline Research and Development Limited410